# Elizabeth Czerepak

> Elizabeth Czerepak is a life sciences finance executive with more than three decades in big pharma, venture capital, and public biotech. She is Chief Financial Officer and VP of Corporate Development at Mirror Biologics, a clinical-stage immunotherapy company in Wesley Chapel, Florida, where she also served as acting CEO from July 2024 to May 2025. Over her career she has helped raise hundreds of millions of dollars, taken companies public through IPOs and SPAC mergers, and worked on landmark pharma transactions including the search that led to BASF Pharma's sale to Abbott. She sits on the boards of Delcath Systems and TransCode Therapeutics.

- **Role:** Chief Financial Officer and VP of Corporate Development at Mirror Biologics, Inc.
- **Organizations:** Mirror Biologics, Inc., Delcath Systems, Inc., TransCode Therapeutics, Inc., Scilex Holding Company, Altimmune, Inc., Cancer Genetics, Inc., BeyondSpring Inc., Isarna Therapeutics, Vaxin, Inc., Bear Stearns Health Innoventures L.P., JPMorgan
- **Nationality:** American
- **Education:** B.A., magna cum laude, Spanish and Mathematics Education, Marshall University, MBA, Rutgers University, Corporate Director Certificate, Harvard Business School
- **Known for:** Helped lead the global partner search for D2E7 (Humira), which culminated in BASF Pharma's $6.9 billion sale to Abbott., Played a key role in Roche's $5.4 billion acquisition of Syntex., Helped take Scilex Holding public through a SPAC merger.

## Career timeline

- **Early career** — Held senior and executive positions over 18 years at BASF (Knoll) Pharmaceuticals, Hoffmann-La Roche, and Merck & Co. in finance, strategic planning, and business development.
- **1990s** — Played a key role in Roche's $5.4 billion acquisition of Syntex; later helped lead the global partner search for D2E7 (Humira), which culminated in BASF Pharma's sale to Abbott for $6.9 billion.
- **Venture capital** — Served roughly 10 years in venture capital as Managing Director at Bear Stearns and JPMorgan, and Founding General Partner of Bear Stearns Health Innoventures L.P.
- **Biotech CFO roles** — Served as CFO of multiple public and private biopharma companies, including Vaxin, Isarna Therapeutics, BeyondSpring, Cancer Genetics, Altimmune, and Scilex Holding.
- **2020** — Elected to the Board of Directors of Delcath Systems, Inc. (effective February 14, 2020).
- **2024** — Appointed Chief Financial Officer and VP of Corporate Development at Mirror Biologics, Inc. (effective April 15, 2024).
- **2024-2025** — Served as acting CEO of Mirror Biologics from July 2024 to May 2025 while continuing as CFO.
- **2025** — Joined the Board of TransCode Therapeutics, Inc. as director and audit chair (October 2025).

## Achievements

- Helped lead the global partner search for D2E7 (Humira), which culminated in BASF Pharma's $6.9 billion sale to Abbott.
- Played a key role in Roche's $5.4 billion acquisition of Syntex.
- Helped take Scilex Holding public through a SPAC merger.
- Helped take Altimmune public via merger with a public company.
- Led an IPO for Cancer Genetics, Inc.
- Helped raise hundreds of millions of dollars for biotechnology companies as an investor, CFO, and board member.
- Serves on the boards of Delcath Systems and TransCode Therapeutics (audit chair).

## Latest updates

- **2025-10** — Joined the Board of Directors of TransCode Therapeutics as a director and audit chair.
- **2025-05** — Concluded her tenure as acting CEO of Mirror Biologics, continuing as CFO.
- **2024-04** — Appointed CFO and VP of Corporate Development at Mirror Biologics.

## Links

- Website: https://mirrorbio.com
- LinkedIn: http://www.linkedin.com/in/elizabethczerepak

---

Profile page: https://yespress.io/elizabeth-czerepak
Published by YesPress — https://yespress.io
Last updated: 2026-07-17